New York is currently home to 4476 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
taVNS for FRNS in Children
Recruiting
Children with frequently relapsing nephrotic syndrome (FRNS) are exposed to prolonged courses of steroids and other immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated non invasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated... Read More
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
06/24/2024
Locations: Cohen Children's Medical Center, New Hyde Park, New York
Conditions: Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
Recruiting
Children with steroid resistant nephrotic syndrome (SRNS) are exposed to prolonged courses of immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated noninvasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated by the inflammatory re... Read More
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
06/24/2024
Locations: Cohen Children's Medical Center, New Hyde Park, New York
Conditions: Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Registry of Asthma Characterization and Recruitment 3 (RACR3)
Recruiting
This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies.
Gender:
ALL
Ages:
All
Trial Updated:
06/24/2024
Locations: Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute, New York, New York
Conditions: Asthma
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
Recruiting
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/24/2024
Locations: Vitreous Retina Macula Consultants Research, New York, New York
Conditions: Age-Related Macular Degeneration
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
Recruiting
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic cancer in patients who have a deleterious or suspected deleterious BRCA1, BRCA2, or PALB2 genetic alteration. The investigational treatment will involve 2 cycles of a combination of intravenous melphalan, BCNU, low-dose I.V. ethanol, vitamin B12b, and vitamin C in association with autologous hematopoietic stem cell infusion. A dose-escalation schedule will be employed fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Breast Cancer Metastatic, Breast Cancer Stage IV, Pancreatic Cancer Stage IV, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma, Adenocarcinoma of the Breast, PALB2 Gene Mutation
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Recruiting
The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity. A phase II study looks at how effective a medication is at treating a specific type of cancer and collects information on the side effects of the study treatment. RET, ROS1, or NTRK fusion or increased MET or AXL activity gene leads to lung cancer cell growth. Cabozantini... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: Memorial Sloan Kettering Commack, Commack, New York
Conditions: Non-Small Cell Lung Cancer
Leflunomide in Patients With PTEN-Altered Advanced Solid Malignancies
Recruiting
Leflunomide in patients with PTEN-null advanced solid tumors. Objectives are to determine the safety and tolerability and the MTD of leflunomide in patients with PTEN-null advanced solid malignancies and to assess preliminary evidence of clinical activity of leflunomide in patients with PTEN-null advanced solid malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/22/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: PTEN-null Advanced Solid Tumors
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Recruiting
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Cholangiocarcinoma
A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
Recruiting
The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
06/21/2024
Locations: Memorial Sloan Kettering Suffolk - Commack (Consent Only), Commack, New York
Conditions: Adenocarcinoma of Lung
Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma
Recruiting
The purpose of this research study is to investigate a shorter radiation treatment schedule for head and neck cancers in patients 70 years of age and older. Standard radiation treatment for head and neck patients normally requires that the patient travel to the hospital daily for 6-7 weeks to receive radiation treatment 5 days per week. This long course of radiation can lead to significant side effects resulting in some people being unable to complete the course of treatment. If this happens, a... Read More
Gender:
ALL
Ages:
70 years and above
Trial Updated:
06/21/2024
Locations: Mount Sinai Downtown Union Square, New York, New York
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Geniculate Artery Embolization for Treatment of Persistent Knee Pain Post Total Knee Arthroplasty
Recruiting
Single-arm, single-center, no sham or placebo, prospective pilot trial designed to evaluate the safety and efficacy of transcatheter arterial embolization in patients with persistent knee pain resistant to conservative management for at least 9 months after total knee arthroplasty (TKA). Eligible participants will receive geniculate artery embolization (GAE) using Embozeneā„¢ Color-Advanced Microspheres. Patients will be followed up for a total of 24 months after GAE.
Gender:
ALL
Ages:
Between 30 years and 85 years
Trial Updated:
06/20/2024
Locations: NYU Langone Health, New York, New York
Conditions: Knee Pain
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists, New York, New York
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)